TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis

TELA Bio (NASDAQ:TELAGet Free Report) and Vivos Therapeutics (NASDAQ:VVOSGet Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for TELA Bio and Vivos Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TELA Bio 0 0 3 0 3.00
Vivos Therapeutics 0 0 0 0 N/A

TELA Bio currently has a consensus target price of $13.67, indicating a potential upside of 177.78%. Given TELA Bio’s higher possible upside, equities analysts clearly believe TELA Bio is more favorable than Vivos Therapeutics.

Profitability

This table compares TELA Bio and Vivos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TELA Bio -79.83% -201.62% -58.60%
Vivos Therapeutics -98.42% -665.17% -122.48%

Volatility and Risk

TELA Bio has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.95, suggesting that its stock price is 695% more volatile than the S&P 500.

Institutional and Insider Ownership

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 5.7% of TELA Bio shares are held by insiders. Comparatively, 9.6% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares TELA Bio and Vivos Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TELA Bio $58.45 million 2.07 -$46.66 million ($2.07) -2.38
Vivos Therapeutics $13.80 million 0.52 -$13.58 million ($11.05) -0.24

Vivos Therapeutics has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

TELA Bio beats Vivos Therapeutics on 9 of the 12 factors compared between the two stocks.

About TELA Bio

(Get Free Report)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.